Agios Pharmaceuticals, Inc.
Symbol: AGIO (NASDAQ)
40.00
▼ (-0.17%) -0.070
Company Description:
Agios Pharmaceuticals Inc is a biopharmaceutical company focused on the field of cellular metabolism to create differentiated medicines for rare diseases, with a focus on classical hematology. The company's primary focus is to develop potentially transformative small-molecule medicines. Its product candidate, Pyrukynd (mitapivat), is an activator of both wild-type and mutant pyruvate kinase enzymes, developed for the treatment of hemolytic anemias. The other drug candidates in its pipeline include Tebapivat (PK activator), being developed as a potential treatment for MDS-associated anemia and sickle cell disease, AG-181 (PAH stabilizer), AG-236, and others.
Key Stats
- Today's Open: $40.36
- Today's High: $40.58
- Today's Low: $39.483
- Today's Volume: 390.00K
- Yesterday Close: $40.07
- Yesterday High: $41.24
- Yesterday Low: $39.67
- Yesterday Volume: 677.71K
- Last Min Volume: 47
- Last Min High: $40
- Last Min Low: $40
- Last Min VWAP: $40
Company Profile
- Name: Agios Pharmaceuticals, Inc.
- Website: https://www.agios.com
- Listed Date: 2013-07-24
- Location: CAMBRIDGE, MA
- Market Status: Active
- CIK Number: 0001439222
- SIC Code: 2834
- SIC description: PHARMACEUTICAL PREPARATIONS
- Market Cap: $2.33B
- Round Lot: 100
- Outstanding Shares: 58.10M
- Asset Type: CS
RECENT FILINGS FOR AGIO
| Filing Date | Filing Type | Format |
|---|---|---|
| 2025-10-02 | 4 | View |
| 2025-09-30 | 4 | View |
| 2025-09-30 | 144 | View |
| 2025-09-26 | 144 | View |
| 2025-09-09 | 4 | View |
| 2025-08-29 | 4 | View |
| 2025-08-28 | SCHEDULE 13G | View |
| 2025-08-27 | 144 | View |
| 2025-08-13 | 4 | View |
| 2025-08-13 | 4 | View |
| 2025-08-12 | 4 | View |
| 2025-08-08 | 144 | View |
| 2025-08-04 | 8-K | View |
| 2025-07-31 | 10-Q | View |
| 2025-07-31 | 8-K | View |
| 2025-07-17 | SCHEDULE 13G/A | View |
| 2025-07-15 | 4 | View |
| 2025-07-11 | 4 | View |
| 2025-07-10 | 144 | View |
| 2025-07-10 | 4 | View |
Latest News on AGIO